Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 8 January 2026 - 9 January 2026

Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

New York, Jan 9, 2026, 11:27 EST — Regular trading Eli Lilly and Company (LLY) shares were down about 0.4% at $1,081 in morning trade on Friday. The drugmaker said this week it will buy autoimmune developer Ventyx Biosciences for $1.2 billion in cash, bringing oral candidates for inflammatory bowel disease into its pipeline. The $14-a-share offer is slated to…
9 January 2026
····
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

NEW YORK, Jan 9, 2026, 10:12 (EST) Amazon Pharmacy said on Friday it now offers Novo Nordisk’s Wegovy weight-loss pill through insurance plans and a cash-pay option, with uninsured customers paying from $149 a month and some commercially insured customers paying $25 for a one-month supply. Amazon said it will add the pill to its pharmacy kiosks in the coming…
9 January 2026
···
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

NEW YORK, Jan 9, 2026, 09:35 EST — Regular session Amazon Pharmacy said it now offers Novo Nordisk’s Wegovy pill through insurance plans and a cash-pay option, widening its push into prescription drugs as demand for weight-loss treatments spreads beyond injections. Eligible customers with commercial insurance may pay as little as $25 for a one-month supply, while customers without insurance…
9 January 2026
····
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

NEW YORK, Jan 9, 2026, 07:03 EST — Premarket Novo Nordisk’s U.S.-listed shares gained 1.4% to $57.34 in premarket trading on Friday after the company rejected claims involving SaveRxCanada.to, a Canadian online pharmacy platform that says it offers India-sourced Ozempic to U.S. patients. SaveRxCanada.to said the pens start at about $280 each, compared with typical U.S. retail prices of $900…
9 January 2026
···
China SXT Pharmaceuticals (SXTC) stock whipsaws after AI “clinics” plan, with Friday open in focus

China SXT Pharmaceuticals (SXTC) stock whipsaws after AI “clinics” plan, with Friday open in focus

New York, Jan 9, 2026, 06:19 EST — Premarket China SXT Pharmaceuticals Inc shares ended Thursday down 37.5% at $1.25 after swinging between $1.21 and $6.98, with volume jumping to about 109.3 million shares, Yahoo Finance data showed. The day before, the stock closed at $2.00 on roughly 115,000 shares. (Yahoo Finance) The China-based maker of traditional Chinese medicine products…
9 January 2026
····
GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

London, Jan 9, 2026, 10:50 GMT — Regular session GSK (GSK.L) shares were down 0.6% at 1,879.5 pence by 1050 GMT, trading in a 1,871p to 1,886p range. (London South East) The stock is still digesting a phase III win for bepirovirsen, GSK’s experimental chronic hepatitis B treatment, which the company says achieved a “functional cure” — meaning the virus…
9 January 2026
··
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

New York, Jan 8, 2026, 19:33 EST — After-hours AbbVie shares dropped 4% on Thursday, slipping to $224.13 in after-hours trading from a previous close of $233.41, as investors digested a profit forecast reduction linked to a hefty charge. The move matters because AbbVie is scrambling to make up lost ground after Humira’s patent expired, leaning heavily on acquisitions to…
9 January 2026
····
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials

MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials

New York, Jan 8, 2026, 17:06 EST — After-hours MoonLake Immunotherapeutics shares jumped 27% to $14.34 on Thursday after the biotech said U.S. regulators supported a route to file its hidradenitis suppurativa treatment without doing more trials for the skin disease. The stock churned between $11.20 and $17.28, and roughly 24 million shares traded. The update is a big deal…
8 January 2026
····
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

New York, Jan 8, 2026, 13:46 EST — Regular session Merck & Co shares rose 1.5% to $110.20 in afternoon trading on Thursday after Wolfe Research upgraded the drugmaker, outpacing a softer health-care sector. The stock traded as high as $112.08 and as low as $107.94, while AbbVie slid about 3.9% and the S&P 500 ETF was little changed. The…
8 January 2026
····
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

New York, Jan 8, 2026, 10:13 EST — Regular session Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner…
8 January 2026
···
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy (TA-TMA). “Median utilization was 8 to 10 vials per treatment course,” Chief Executive…
8 January 2026
····
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

New York, January 8, 2026, 05:14 (EST) — Premarket AbbVie Inc (ABBV) shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing The whiplash matters because…
8 January 2026
···
1 … 9 10 11 12 13 … 45

Stock Market Today

  • Vanguard S&P 500 ETF Gains 17% in 12 Months, Faces High Valuation Concerns
    January 22, 2026, 11:24 AM EST. The Vanguard S&P 500 ETF (VOO) delivered a strong 17% total return over the past year, reflecting solid U.S. economic growth and the power of 500 leading companies. Over the past decade, VOO's annualized return reached about 15.9%, helped by low interest rates, tech sector dominance, and a surge in passive investing. However, market experts warn of stretched valuations, with the cyclically adjusted price-to-earnings (CAPE) ratio hitting 40.8, a level only seen during the 1999-2000 dot-com boom. This metric signals potential pressure on future returns, suggesting the ETF may face headwinds if valuations normalize.
Go toTop